ReviR Therapeutics Receives FDA Rare Pediatric Disease Designation for RTX-117 in Charcot-Marie-Tooth Disease
核心洞察
The FDA granted Rare Pediatric Disease Designation (RPDD) to ReviR Therapeutics (搜索)' investigational oral small molecule RTX-117 (搜索) for Charcot-Marie-Tooth disease (搜索) (CMT), applying broadly rather than to a specific subtype.
RTX-117 (搜索) is a potential first-in-class therapy that modulates the integrated stress response (ISR) pathway by activating eIF2B (搜索) to restore mRNA translation and protein-expression homeostasis.
If approved and meeting statutory criteria, ReviR may become eligible for a transferable Rare Pediatric Disease Priority Review Voucher with potential commercial value.
ReviR Therapeutics (搜索), a clinical-stage biotechnology company advancing small-molecule therapies through the integration of artificial intelligence and RNA biology, announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to RTX-117 (搜索), its investigational oral small-molecule candidate, for development in Charcot-Marie-Tooth disease (搜索) (CMT). The designation applies to CMT broadly and is not limited to a specific subtype.
The FDA's RPDD program is intended to encourage the development of therapies for serious or life-threatening rare diseases that predominantly affect children. If RTX-117 (搜索) is ultimately approved and meets applicable statutory requirements and program criteria, ReviR may be eligible to receive a Rare Pediatric Disease Priority Review Voucher (PRV). The voucher may be transferred to another sponsor or redeemed to obtain priority review for a future marketing application and may hold potential commercial value for ReviR.
Unmet Need in Charcot-Marie-Tooth Disease
CMT comprises a group of progressive inherited neuromuscular disorders that often emerge during childhood or adolescence. Patients may experience leg weakness and muscle wasting, skeletal deformities, pain, sensory impairment and delayed motor development. Despite the longstanding need for new treatment options, there are currently no approved disease-modifying therapies for CMT.
Mechanism of Action and Platform
RTX-117 (搜索) is ReviR's investigational therapy developed through the company's proprietary VoyageR AI platform and is designed to modulate the integrated stress response (ISR) pathway. By activating eIF2B (搜索), RTX-117 is intended to restore normal mRNA translation and protein-expression homeostasis. ReviR is advancing the program in CMT while expanding its translational research in ISR-related diseases, including fibrotic conditions.
The candidate is described as a potential first-in-class, orally administered small-molecule therapy, with discovery and molecular design supported by XtalPi (搜索)'s AI and robotics-enabled drug discovery platform. eIF2B (搜索) serves as a key regulator of protein translation, and by restoring mRNA translation and protein-expression homeostasis, the program aims to address molecular mechanisms implicated in ISR-related diseases.
Clinical Development Status
Previously, RTX-117 (搜索) has received FDA Orphan Drug Designation (ODD) for CMT and clinical trial authorizations in both the United States and China. The program is currently in Phase 1 clinical development, with completion of the Phase 1 study anticipated by the end of this year. RTX-117 has secured Investigational New Drug (IND) clearance for CMT and VWM in the United States and China, and ReviR is expanding development into additional ISR-related indications, including fibrotic diseases.
Leadership Perspective
"People living with CMT, particularly children, urgently need more effective disease-modifying treatment options," said Paul R. August, Ph.D., Chief Scientific Officer of ReviR Therapeutics (搜索). "This designation provides additional support for the continued development of RTX-117 (搜索). As the CMT program progresses, we will continue to build clinical and translational evidence that may inform our work in additional ISR-related diseases."
"RPDD adds another important strategic dimension to the global development of RTX-117 (搜索)," said Peng Yue, Ph.D., Co-founder and CEO of ReviR Therapeutics (搜索). "The experience and capabilities we build through RTX-117 will help inform the expansion of our small-molecule RNA platform into a broader range of serious diseases, including genetic diseases, immunology and inflammation, and oncology. We look forward to working with partners worldwide to advance new therapeutic options for patients."
ReviR Therapeutics (搜索) was founded in 2021 by leaders in computational biology, RNA biology, genomics and drug discovery, and develops therapies across neurology, immunology and inflammation, and oncology. The company's lead clinical-stage program, RTX-117 (搜索), is advancing across multiple ISR-related disease areas, including CMT and VWM, with fibrotic diseases among the additional indications under exploration.